loading
前日終値:
$49.44
開ける:
$49.47
24時間の取引高:
664.50K
Relative Volume:
0.76
時価総額:
$3.03B
収益:
$45.48M
当期純損益:
$169.95M
株価収益率:
18.66
EPS:
2.62
ネットキャッシュフロー:
$230.85M
1週間 パフォーマンス:
-7.16%
1か月 パフォーマンス:
+34.51%
6か月 パフォーマンス:
+9.69%
1年 パフォーマンス:
+68.96%
1日の値動き範囲:
Value
$48.80
$50.48
1週間の範囲:
Value
$48.80
$53.70
52週間の値動き範囲:
Value
$24.22
$60.60

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name
名前
Protagonist Therapeutics Inc
Name
セクター
Healthcare (1166)
Name
電話
(510) 474-0170
Name
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Name
職員
0
Name
Twitter
Name
次回の収益日
2024-11-04
Name
最新のSEC提出書
Name
PTGX's Discussions on Twitter

PTGX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PTGX
Protagonist Therapeutics Inc
48.88 3.03B 45.48M 169.95M 230.85M 2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-06 開始されました BMO Capital Markets Outperform
2024-12-06 開始されました Goldman Neutral
2024-11-05 開始されました Wedbush Outperform
2024-09-24 開始されました TD Cowen Buy
2024-09-09 開始されました Truist Buy
2023-10-30 開始されました CapitalOne Overweight
2023-05-25 再開されました Jefferies Buy
2022-08-25 開始されました JMP Securities Mkt Outperform
2022-02-11 開始されました BTIG Research Buy
2021-10-12 アップグレード JP Morgan Neutral → Overweight
2021-10-11 アップグレード Northland Capital Market Perform → Outperform
2021-09-20 ダウングレード JP Morgan Overweight → Neutral
2021-05-24 開始されました JMP Securities Mkt Outperform
2021-05-24 開始されました Northland Capital Outperform
2021-01-06 開始されました JP Morgan Overweight
2020-12-16 開始されました Piper Sandler Overweight
2020-09-18 繰り返されました H.C. Wainwright Buy
2020-07-15 開始されました Jefferies Buy
2020-05-18 繰り返されました H.C. Wainwright Buy
2019-07-08 開始されました H.C. Wainwright Buy
2019-05-09 アップグレード Stifel Hold → Buy
2018-12-06 開始されました Nomura Buy
2018-01-29 開始されました Stifel Buy
2017-07-21 開始されました BTIG Research Buy
すべてを表示

Protagonist Therapeutics Inc (PTGX) 最新ニュース

pulisher
Mar 25, 2025

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance

Mar 25, 2025
pulisher
Mar 23, 2025

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Bluefield Daily Telegraph

Mar 23, 2025
pulisher
Mar 22, 2025

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - MSN

Mar 22, 2025
pulisher
Mar 21, 2025

Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus.com

Mar 21, 2025
pulisher
Mar 20, 2025

Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm - Business Wire

Mar 20, 2025
pulisher
Mar 19, 2025

Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Protagonist Therapeutics director Waddill sells $217,000 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 18, 2025

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company

Mar 18, 2025
pulisher
Mar 18, 2025

Fast Company Ranks Protagonist Among Elite Biotech Innovators: 2 FDA Filings Coming - StockTitan

Mar 18, 2025
pulisher
Mar 15, 2025

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 15, 2025
pulisher
Mar 15, 2025

Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock By Investing.com - Investing.com South Africa

Mar 15, 2025
pulisher
Mar 15, 2025

Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock By Investing.com - Investing.com Canada

Mar 15, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $76.00 - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Victory Capital Management Inc. - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Learn to Evaluate (PTGX) using the Charts - Stock Traders Daily

Mar 12, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $72.00 at BMO Capital Markets - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High on Analyst Upgrade - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthroug - GuruFocus.com

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics price target raised to $76 from $60 at Truist - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success - Yahoo Finance UK

Mar 11, 2025
pulisher
Mar 11, 2025

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up - Simply Wall St

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics Gets IBD Stock Rating Upgrade - Investor's Business Daily

Mar 11, 2025
pulisher
Mar 11, 2025

10 Firms Buck Market Bloodbath on Monday - Insider Monkey

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics’ (PTGX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

PTGX stock soars to 52-week high, reaching $50.18 By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

BTIG maintains Buy on Protagonist Therapeutics, target at $73 By Investing.com - Investing.com Canada

Mar 10, 2025

Protagonist Therapeutics Inc (PTGX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):